Answers are grounded in this paper and cite their sources.
Thrombotic thrombocytopenic purpura (TTP) is an ultra-rare blood disorder, characterized by severe ADAMTS13 deficiency. Affected individuals present with potentially life-threatening acute events and may experience sub-acute and chronic TTP manifestations often resulting in long-term organ damage. Incremental symptom prevalence before, during, and after an acute event as well as healthcare resource utilization (HCRU) and costs during and after an acute event were compared between people with TTP and matched non-TTP controls.
No takes yet. Share an insight, caveat, or question.
Xing et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: